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Abstract
Background: Methamphetamine (MA) is a potent stimulant that is readily available. Its effects are similar to cocaine, but
the drug has a profile associated with increased acute and chronic toxicities. The objective of this systematic review was
to identify and synthesize literature on risk factors that are associated with MA use among youth.
More than 40 electronic databases, websites, and key journals/meeting abstracts were searched. We included studies
that compared children and adolescents (≤ 18 years) who used MA to those who did not. One reviewer extracted the
data and a second checked for completeness and accuracy. For discrete risk factors, odds ratios (OR) were calculated
and when appropriate, a pooled OR with 95% confidence intervals (95% CI) was calculated. For continuous risk factors,
mean difference and 95% CI were calculated and when appropriate, a weighted mean difference (WMD) and 95% CI was
calculated. Results were presented separately by comparison group: low-risk (no previous drug abuse) and high-risk
children (reported previous drug abuse or were recruited from a juvenile detention center).
Results: Twelve studies were included. Among low-risk youth, factors associated with MA use were: history of heroin/
opiate use (OR = 29.3; 95% CI: 9.8–87.8), family history of drug use (OR = 4.7; 95% CI: 2.8–7.9), risky sexual behavior
(OR = 2.79; 95% CI: 2.25, 3.46) and some psychiatric disorders. History of alcohol use and smoking were also significantly
associated with MA use. Among high-risk youth, factors associated with MA use were: family history of crime (OR = 2.0;
95% CI: 1.2–3.3), family history of drug use (OR = 4.7; 95% CI: 2.8–7.9), family history of alcohol abuse (OR = 3.2; 95%
CI: 1.8–5.6), and psychiatric treatment (OR = 6.8; 95% CI: 3.6–12.9). Female sex was also significantly associated with
MA use.
Conclusion: Among low-risk youth, a history of engaging in a variety of risky behaviors was significantly associated with
MA use. A history of a psychiatric disorder was a risk factor for MA for both low- and high-risk youth. Family
environment was also associated with MA use. Many of the included studies were cross-sectional making it difficult to
assess causation. Future research should utilize prospective study designs so that temporal relationships between risk
factors and MA use can be established.
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Background
Methamphetamine (MA), also known as crystal meth, is a
synthetic stimulant that affects the brain and central nerv-
ous system[1-4]. Smoking is the most common route of
administration for MA[5]. When smoked or injected, it
produces an initial rush that lasts only a couple of minutes
but is intensely pleasurable[5]. This is followed by a pro-
longed high that results in an extended period of eupho-
ria[5]. The half-life of MA ranges from 10–30 hours
depending on the purity of the drug, urine pH, and the
amount consumed[2]. Like other psychoactive drugs of
abuse, chronic MA use can result in tolerance, where
increased amounts of MA are required to produce the
same high[6].
Because MA is a stimulant, it produces physiological and
psychological effects similar to those elicited by
cocaine[1]. MA stimulates the release of dopamine, nore-
pinephrine, and serotonin, and blocks their reuptake[7].
This excess amount of neurotransmitters in the synapses
produces sensations of euphoria, lowered inhibitions,
feelings of invincibility, increased wakefulness, height-
ened sexual experiences, and hyperactivity resulting from
increased energy for extended periods of time[8]. Delete-
rious short-term effects include increased heart and respi-
ration rates, hyperthermia, chest pain, hypertension,
increased respiration, decreased appetite, anorexia, irrita-
bility, confusion, tremors, convulsions, anxiety, aggres-
siveness, and symptoms of psychosis such as
hallucinations and paranoia[4,9,10]. This is followed by
mental and physical exhaustion, headaches, irritability,
reduced concentration, hunger, decreased energy, anhe-
donia, and a craving for more MA[3,11]. Cognitive
impairments and changes in the brain that result in symp-
toms similar to those of Parkinson's disease can
occur[12,13]. Long-term use of MA use is associated with
neurotoxicity, neurodegeneration, and clinical depression
that may lead to homicidal and suicidal ideation and
action[5].
MA is produced, or "cooked" quickly, reasonably simply,
and cheaply by using legal and readily available ingredi-
ents, including ephedrine, pseudoephedrine, red phos-
phorous, iodine, ammonia, paint thinner, lye, camping
fuel, drain cleaner, and lithium[5]. These components
and cooking tools can be purchased at local drug stores
and hardware stores, and recipes can be found on the
Internet[14]. Many of the chemicals used in the produc-
tion of MA are explosive and the generated waste products
are corrosive and toxic[15].
In 2004, the US National Survey on Drug Use and Health
surveyed persons over the age of 11 and found that 1.4
million people (0.6% of the population) had used MA in
the past 12 months, and 600,000 (0.2%) had used it in
the previous month[16]. School-based drug surveys
administered in Ontario and Manitoba specifically asked
about MA use[17,18]. They found that between 2.7% and
3.3% of students reported using MA within the last year.
In another Canadian province, 4% (108,000) of Albertans
aged 15 or older reported using more than one ampheta-
mine-type stimulant[4]. In 2002, street youth aged 14–30
years were surveyed and 71% of respondents reported
using amphetamine-type stimulants and 57% had used
them on more than ten occasions[4].
Because MA is easily accessible, relatively cheap, and has
reinforcing properties, chronic use can pose a significant
danger[4]. If risk factors for MA use could be identified,
physicians and other health care professionals who work
with youth may be better equipped to identify MA users
and develop education and prevention programs that
could be targeted to youth at greater risk for using MA.
Thus, we performed a systematic review to identify factors
at the individual, family, and community level that are
associated with MA use among children and adolescents.
Methods
Literature search
We searched over 40 electronic databases, including
MEDLINE®, Ovid MEDLINE® In-Process & Other Non-
Indexed Citations, EBM Reviews – Cochrane Central Reg-
ister of Controlled Trials, EMBASE, CINAHL®, PsycINFO®,
International Pharmaceutical Abstracts, Pascal, Global
Health, Science Citation Index Expanded and Social Sci-
ences Citation Index (via Web of Science®), Social Sciences
Abstracts, and Psychology and Behavioral Sciences Collec-
tion. Trials registers (Current Controlled Trials, Clinical-
Trials.gov, the Australian Clinical Trials Registry, and the
National Research Register in the United Kingdom) were
searched for additional trials. Search terms such as meth-
amphetamine, variant spellings of methamphetamine,
amphetamine-related disorders, and crystal meth, were
adapted for each database and appropriate subject head-
ings and keywords were used. In addition, an extensive
search for grey literature was conducted. Hand searching
was conducted in relevant scientific journals, scientific
meetings, and the reference lists of relevant reviews and
included studies were reviewed. We restricted the search
results to English-language studies. The literature search is
considered up to date as of May 15, 2006. Full search strat-
egies and lists of resources searched are available [see
Additional file 1].
Study selection and inclusion criteria
Two reviewers independently screened the titles and,
when available, the abstracts. Based on general inclusion
criteria, studies were classified as "potentially relevant",
"irrelevant", and "unclear". The full text of studies
described as "potentially relevant" and "unclear" wasBMC Pediatrics 2008, 8:48 http://www.biomedcentral.com/1471-2431/8/48
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obtained and two reviewers independently applied the
specific inclusion criteria. Studies were included if they
compared children ≤ 18 years of age who did and did not
use MA (the comparison group could be other drug users
or children who do not use drugs). The following study
designs were included: case-control, cohort, and cross-sec-
tional. Studies were excluded if they did not have a com-
parison group, if the outcomes were not measured
quantitatively or if they were uncontrolled before and
after studies, case-series, or case studies. Disagreements
were resolved through discussion or through third party
adjudication, as necessary.
Methodological quality assessment
Two reviewers independently assessed methodological
quality; discrepancies were resolved through consensus or
by third party adjudication as required. Observational
studies were assessed using the Downs and Black check-
list[19]. This tool comprises six sections that assess report-
ing, external validity, internal validity (bias), internal
validity (confounding), and power.
Data extraction
Data were extracted by one reviewer and checked for accu-
racy and completeness by a second reviewer. A standard
data extraction form was developed and the data were
subsequently entered into an electronic database. For each
included study, we extracted information about the popu-
lation (demographics and sources), type of study (study
design, prospective or retrospective data collection), defi-
nitions and details of risk factors, and the numeric results.
Data analysis
After reviewing the studies that met our inclusion criteria,
we made a post hoc decision to group the studies and con-
duct the data analysis by the nature of the comparison
group: 1) youth who did not use illicit drugs (referred to
as "low-risk") and 2) youth who abused illicit drugs other
than MA or were recruited from juvenile detention centers
(referred to as "high-risk"). For dichotomous risk factors
(e.g., sex) we calculated pooled odds ratios (OR) with
95% confidence intervals (95% CI), where appropriate.
For continuous risk factors (e.g., years of education) we
calculated weighted mean difference (WMD) and 95% CI
using the DerSimonian and Laird random effects
model[20]. A random effects model was used because it
allows for combining heterogeneous results where the
heterogeneity cannot readily be explained[21]. The result-
ing estimate is more conservative because the resulting
confidence intervals are wider. Statistical heterogeneity
was assessed using the I2 statistic, which describes the per-
centage of total variation across studies that is due to het-
erogeneity rather than chance. For this review a value
greater than 50% was considered as substantial heteroge-
neity[22]. In instances where only one study reported the
specific risk factor or where pooling was not appropriate,
the effect estimate (OR or WMD) and 95% CI were
reported for each risk factor.
Results
Literature search
The database, grey literature searches and hand searching
yielded 2,376 potentially relevant studies. In total, 106
unique studies were reviewed and 13 met our inclusion
criteria. Of these, two studies assessed risk factors in the
same population and are treated as one study for the pur-
poses of this report[23]. Therefore, our review includes 13
publications but only 12 unique studies. Study retrieval
and selection is outlined in Figure 1.
Studies were excluded from the review for the following
reasons: not relevant to the topic (n = 34), incorrect study
population (n = 33), inappropriate study design (n = 12),
not primary research (n = 13), and inadequate data (n =
1).
Description of included studies
The characteristics of the 12 included studies and popula-
tions are presented in Tables 1 [see Additional file 2] and
2 [see Additional file 3]. Most studies relied on self-
reported MA use. Three studies administered urine tests to
determine MA use[24-26] and one study diagnosed chil-
dren with MA dependence[27]. The remaining studies
relied on self-reported MA use. Seven studies were con-
ducted in North America [27-33] and the remaining five
in Asia[23,24,26,34,35]. The majority of the studies were
published recently; the median year of publication was
2004. The median sample size was 604 and ranged from
60 to 78,715. Three studies used a case-control design and
the remaining nine were cross-sectional.
In five studies, youth who reported using MA were com-
pared to youth who did not use illicit drugs, hereafter
referred to as "low-risk" youth. These low-risk youth were
sampled from school populations. For the remaining
seven studies, youth who reported using MA were com-
pared to youth who abused illicit drugs other than MA,
and/or youth who were sampled from juvenile detention
centers, hereafter referred to as "high-risk" youth. Youth
were recruited from a variety of locations, including
schools, detention centers, juvenile homes, or treatment
facilities. One study included youth up to the age of 24
and one study did not report the age of participants. The
studies assessed a variety of risk factors, including demo-
graphic variables, mental health status, and risky behav-
iors.
Methodological quality of included studies
The median Downs and Black score was 15 of a possible
score of 29 and ranged from 12 to 28 [Table 1] suggesting
a risk of bias for those studies that received lower quality
scores. Six of the twelve studies reported adjusted results,BMC Pediatrics 2008, 8:48 http://www.biomedcentral.com/1471-2431/8/48
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that is, the risk factor of interest was adjusted for other
potentially confounding risk factors[23,26,28,31,32,34].
Six studies disclosed their funding source and the most
common source was a government agency[23,26,29,
30,32].
Quantitative results: comparing MA users to low-risk 
youth
Five studies compared risk factors for MA among low-risk
youth, as defined above (Table 2) [23,24,26,28,29]. There
was considerable heterogeneity among the studies, which
precluded the calculation of pooled estimates of effects in
most cases. Pooled estimates are presented where appro-
priate.
Sex
Two cross-sectional studies examined sex as a risk factor
and both independently indicated a significant associa-
tion showing that males are more likely to use MA than
females[26,29].
Ethnicity
One cross-sectional study using survey data examined eth-
nicity as a risk factor for MA[29]. The results showed that
Caucasian youth were more likely to use MA than African-
American youth and Asian youth. However, Caucasian
youth were significantly less likely to use MA than His-
panic and Native American youth.
Years of education
One case-control[23] and two cross-sectional stud-
ies[24,26] examined education as a risk factor for MA use
and all three studies concluded that MA use was signifi-
cantly associated with fewer years of education. Two stud-
ies reported the mean years of education among MA users
and non-MA users. The pooled WMD indicated that non-
MA users had more years of education than youth who
used MA (WMD = 2.63; 95% CI: 2.45 to 2.80)[24,25]. The
third study categorized respondents' educational attain-
ment of Grades 1–3 versus Grades 4 or more and also
showed that non-MA users were 1.3 times more likely to
have more education (95% CI: 1.06 to 1.62)[26].
Sexual behavior
Two cross-sectional studies independently reported a sig-
nificant association between having ever previously
engaged in sexual intercourse and using MA[8,36]. One
study found the following behaviors were significantly
associated with MA use: engaging in unprotected sex,
engaging in unplanned sex under the influence of alcohol,
and engaging in sexual intercourse with an alcohol-intox-
icated partner[24].
Alcohol, cigarette and opiate use
Two studies (one case-control[23] and one cross-sec-
tional[26]) independently reported statistically signifi-
cant associations between alcohol use, smoking, and
heroin/opiate use.
Psychiatric disorders
Two studies of the same population examined the rela-
tionship between psychiatric disorders and MA use; how-
ever, the studies did not examine the same psychiatric
conditions and their results could not be pooled[23,25].
The presence of the following conditions were found to be
significantly associated with MA use: having any psychiat-
Study retrieval and selection of studies investigating risk factors for MA use Figure 1
Study retrieval and selection of studies investigating risk factors for MA use.BMC Pediatrics 2008, 8:48 http://www.biomedcentral.com/1471-2431/8/48
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ric disorder, adjustment disorder, conduct disorder, and
attention deficit and hyperactivity disorder (ADHD).
Oppositional defiance disorder, anxiety disorder, major
depressive disorder, dysthmic disorder, bipolar disorder,
and eating disorder were not significantly associated with
MA use among low-risk youth.
Other risk factors
Several other risk factors were associated with MA use
among low-risk youth: being homosexual or bisexual[28],
experiencing disruptive parenting[23], peers using or pro-
viding MA[23], and family history of drug use[23].
Multivariate analyses
Three studies conducted adjusted or multivariable logistic
regression analyses (i.e., the risk factor of interest was
adjusted for other potentially confounding factors).
Lampinen et al. found that age and sexual preference were
significant risk factors for MA use; sex was not found to be
a risk factor in their analysis[28]. After adjusting for other
psychiatric conditions and peer and family characteristics,
Sattah et al. reported that the following risk factors were
associated with MA use: recent alcohol or tobacco use, his-
tory of marijuana use, not having a family confidant, peer
pressure, having a positive attitude towards MA use, and
sexual experience[26]. The third study found that conduct
disorder, a positive attitude toward MA use, poor under-
standing of MA use, disruptive parenting, low level of car-
egiver education, friends using or providing MA, and a
more interactive interaction with peers were significant
risk factors for MA[25]. Sex was not found to be statisti-
cally significant in this multivariable analysis.
Quantitative results: comparing MA users to high-risk 
youth
Seven studies examined risk factors for MA among high-
risk youth (Table 3)[27,30-35]. Because of substantial het-
erogeneity among the studies, pooling of estimates was
generally not appropriate.
Sex
Five studies (one case-control and four cross-sectional)
independently reported that female sex was significantly
associated with MA use[30,31,33-35].
Table 1: Risk factors for MA: quality of included studies
Study Year Study Design Downs and Black Score Present Adjusted OR Funding Source
Low-risk youth as the comparison group
Lampinen 2006 Cross-sectional 15 Yes Other
Oetting 2000 Cross-sectional 12 No Government
Sattah 2002 Cross-sectional 15 Yes Government
Yen 2006a Case-control 15 Yes Government
Yen 2004b Cross-sectional 13 No NR
High-risk youth as the comparison group
Kim 2002 Cross-sectional 16 No Government
Miura 2006 Case-control 15 Yes NR
Palmer 2005 Case-control 13 No NR
Rawson 2005 Cross-sectional 14 Yes NR
Shillington 2005 Cross-sectional 18 Yes Other
Shillington 2003 Cross-sectional 17 No NR
Uchida 1995 Cross-sectional 12 No NR
a Age and sex matched
b Sex matchedBMC Pediatrics 2008, 8:48 http://www.biomedcentral.com/1471-2431/8/48
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Age
One cross-sectional study categorized participants into
two age groups: 13–14 years and 15–18 years[31]. The
results show that age was not significantly associated with
MA use.
Ethnicity
Three studies (one case-control and two cross-sectional)
examined the association between ethnicity and MA use
among high-risk youth[27,31,32]. Compared to African-
American and Asian youth, Caucasian youth were signifi-
cantly more likely to use MA. There was no significant dif-
Table 2: Comparing MA users to Low-Risk Youth
Risk Factor Study Statistical Measure Point Estimate (95% CI) Conclusion
Sexa Oetting 2000 OR 0.72 (0.70, 0.75) Odds of using MA were higher for 
males.
Sattah 2002 OR 0.34 (0.27, 0.43)
Years of education Yen 2004 MD 2.70 (2.36, 3.04) Odds of using MA were higher for 
those with less education.
Yen 2006 MD 2.60 (2.40, 2.80)
Pooledb WMD 2.63 (2.45, 2.80)
Sattah 2002 OR 1.31 (1.06, 1.62)
Sexual behavior Sattah 2002 OR 2.79 (2.25, 3.46) Odds of using MA was higher for those 
who had previously engaged in sexual 
intercourse.
Yen 2004 OR 31.79 (15.56, 64.93)
Alcohol use Sattah 2002 OR 8.02 (4.53, 14.18) Odds of using MA was higher for those 
who drink alcohol.
Yen 2006 OR 51.31 (12.27, 214.68)
Heroin/opiate use Sattah 2002 OR 30.66 (9.38, 100.17) Odds of using MA was higher for those 
who had a history of heroin/opiate use.
Yen 2006 OR 22.53 (1.24, 409.59)
Smoking Sattah 2002 OR 13.72 (10.69, 17.60) Odds of using MA were higher for 
those who smoke.
Yen 2006 OR 154.85 (81.95, 292.60)
Family history of drug use Yen 2006 OR 8.65 (3.88, 19.25) Odds of using MA were higher for 
youth with family history of drug use.
Homosexual or bisexual Lampinen 2006 OR 17.02 (4.83, 60.01) Odds of using MA were higher for 
youth who were homosexual or 
bisexual.
Experiencing disruptive parenting Yen 2006 OR 7.84 (5.25, 11.71) Odds of using MA were higher for 
youth who experienced disruptive 
parenting.
Peers using or providing MA Yen 2006 OR 40.94 (24.64, 68.03) Odds of using MA were higher for 
youth with peers using or providing 
MA.
Engaging in unprotected sex Yen 2004 OR 15.68 (8.04, 30.58) Odds of using MA were higher for 
youth who engaged in unprotected 
sex.
Engaging in unplanned sex under 
the influence of alcohol
Yen 2004 OR 70.42 (9.34, 531.06) Odds of using MA were higher for 
youth who engaged in unplanned sex 
under the influence of alcohol.
Engaging in sex with an alcohol-
intoxicated partner
Yen 2004 OR 29.33 (6.70, 128.36) Odds of using MA were higher for 
youth who engaged in sexual 
intercourse with an alcohol-
intoxicated partner.
Any psychiatric disorder Yen 2006 OR 3.05 (2.12, 4.39) Odds of using MA were higher for 
youth who had any psychiatric 
disorder.
Adjustment disorder Yen 2006 OR 2.89 (1.53, 5.47) Odds of using MA were higher for 
youth who had adjustment disorder.
Conduct disorder Yen 2006 OR 31.91 (16.06, 63.41) Odds of using MA were higher for 
youth who had conduct disorder.
Attention-deficit hyperactivity 
disorder
Yen 2006 OR 2.84 (1.81, 4.47) Odds of using MA were higher for 
youth who had ADHD.
a Female = 1, Male = 0
b Combine Yen 2004 and Yen 2006, I2 = 0%BMC Pediatrics 2008, 8:48 http://www.biomedcentral.com/1471-2431/8/48
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ference in MA use between Caucasian versus Hispanic,
Asian, or Native American.
Alcohol use
One cross-sectional study found no association between a
history of alcohol use and MA use[31].
Family history
One cross-sectional study found that a family history of
crime or drug use was significantly associated with MA
use[34]. The pooled analysis of two cross-sectional studies
showed a significant association between family history of
alcohol abuse and MA use[34,35].
Table 3: Comparing MA Users to High-Risk Youth
Risk Factor Study OR (95% CI) Conclusion
Sexa Uchida 1995 6.55 (2.34, 18.34) Females were more likely to use MA than males.
Kim 2002 1.53 (1.27, 1.85)
Shilungton 2003 4.00 (3.49, 4.58)
Rawson 2005 9.53 (5.40, 16.79)
Miura 2006 4.57 (2.92, 7.17)
Ageb Rawson 2005 2.10 (0.84, 5.26) Age was no significantly associated with MA use.
Alcohol use Rawson 2005 1.04 (0.56, 1.95) No association between a history of alcohol use and MA 
use
Family history of crimec Miura 2006 2.00 (1.22, 3.29) Odds of using MA was higher for youth with family history 
of crime.
Family history of drug use Miura 2006 4.70 (2.79, 7.90) Odds of using MA was higher for youth with family history 
of drug use.
Family history of alcohol abuse Uchida 1995 3.61 (1.39, 9.39) Odds of using MA was higher for youth with family history 
of alcohol abuse.
Miura 2006 2.94 (1.44, 6.00)
Pooledc 3.16 (1.78, 5.61)
Child abuse Uchida 1995 3.13 (1.24, 7.92) Odds of using MA was higher for youth who experienced 
child abuse; the association was not statistically significant.
Miura 2006 1.49 (0.73, 3.07)
Pooledd 2.04 (0.99, 4.17)
Receiving psychiatric treatment Miura 2006 6.78 (3.55, 12.94) Odds of using MA was higher for youth who were receiving 
psychiatric treatment.
Greater than two admissions to juvenile home Miura 2006 2.70 (1.77, 4.13) Odds of using MA was higher for youth with greater than 
two admissions to juvenile home.
History of violence Miura 2006 0.35 (0.20, 0.62) Odds of using MA was lower for youth with history of 
violence.
Strict parental monitoring Shillington 2005 0.25 (0.11, 0.57) Odds of using MA was lower for youth with strict parental 
monitoring.
a Female = 1, Male = 0
b 13–14 years vs. 15–18 years
c I2 = 0%
d I2 = 34.7%BMC Pediatrics 2008, 8:48 http://www.biomedcentral.com/1471-2431/8/48
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Child abuse
The pooled analysis of one cross-sectional and one case-
control study showed a two-fold association between chil-
dren who experienced abuse and MA use; however, the
result was not statistically significant[34,35].
Other risk factors
The following factors were significantly associated with
MA use: receiving psychiatric treatment, greater than two
admissions to juvenile home, and history of violence[34].
However, strict parental monitoring was found to be pro-
tective for MA use among high-risk youth[32].
Multivariable analyses
Three studies conducted a multivariable logistic regres-
sion analysis. Shillington et al. found that strict parental
monitoring, after controlling for age, was a statistically
significant protective factor against MA use among high-
risk youth[32]. After controlling for age and race, Rawson
et al. found that female sex was significantly associated
with MA use[31]. In the third study, female sex, age, more
than two admissions to a juvenile home, non-violent his-
tory, psychiatric treatment, family history of drug misuse,
and child abuse were significantly associated with MA use;
a family history of crime was not significantly associated
with MA use[34].
Discussion and conclusion
This systematic review presents the best-available evi-
dence regarding risk factors for MA use among youth. An
exhaustive search of over 40 electronic databases, grey lit-
erature, and hand searching identified 12 unique studies
that met our inclusion criteria. The majority of the studies
(9/12) were cross-sectional in design and therefore it is
not possible to determine whether the risk factors precede
or follow MA use.
Because we believe that factors associated with MA use
may differ among socially integrated (i.e., low-risk) and
marginalized (i.e., high-risk) youth, we chose to analyze
these studies separately. Compared to low-risk youth,
there were some clear patterns of risk factors associated
with MA use. A history of engaging in a variety of risky
behaviors (e.g., sexual activity [planned, unplanned, or
under the influence of alcohol], alcohol consumption,
and opiate use) was significantly associated with MA use
among low-risk youth. Engaging in high-risk behavior
may be a gateway for MA use or vice versa. Homosexual or
bisexual lifestyle is also a risk factor. This is not surprising,
as MA is believed to heighten sexual pleasure and gay and
bisexual men cite this as a reason for using MA[36]. A his-
tory of a psychiatric disorder and, in particular, adjust-
ment disorder, conduct disorder, or ADHD, is a risk factor
for MA use. This is consistent with previous research that
shows psychiatric conditions to be risk factors for drug use
in general[37].
Several risk factors were associated with MA use among
high risk youth (i.e., those that used other illicit drugs or
were in detention/juvenile centers). Unlike low-risk
youth, females were significantly more likely to use MA.
Youth who grew up in an unstable family environment
(e.g., family history of crime, alcohol use, and drug use)
were significantly more likely to use MA. While child
abuse was not a significant risk factor, it approached sta-
tistical significance. High-risk youth who had received
treatment for psychiatric conditions were more likely to
use MA. One study found that strict parental monitoring
was found to be protective against MA use among this
group of youth.
Limitations
There were only 12 studies that met our inclusion criteria.
These studies were fairly heterogeneous, which precluded
pooling of results for most risk factors. Furthermore,
many of the risk factors were assessed in only one study
and the sample size was small. This is reflected in the wide
confidence intervals and imprecise effect estimates. Most
studies were either cross-sectional or retrospective making
it impossible to assess a causal relationship between the
risk factors and MA use. As with any systematic review,
there is the possibility of publication and selection bias.
However, we feel the risk for publication bias was mini-
mized by our exhaustive search process. In addition to
electronic databases, the reference lists of the included
studies were searched, relevant conference proceedings
and key journals were hand searched, and a thorough grey
literature search was conducted.
Implications for clinicians and front-line workers
Youth who engage in risk-taking behaviors, live in an
unstable home environment, have a psychiatric condi-
tion, and have peers that use or sell MA have a higher pro-
pensity for MA use. In order to identify youth at risk for
MA use, health care workers and counsellors need to con-
duct a holistic assessment that includes psychiatric, life-
style, and family history.
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